A Real-world Study to Evaluate the Efficacy of 650nm Low-intensity Single-wavelength Red Light in the Prevention and Control of Myopia in Children and Adolescents

What this Trial Is About

Researchers are evaluating the effectiveness and safety of low-level 650nm red-light irradiation in controlling and preventing myopia in children and adolescents aged 7 to 18 years. This real-world study includes children who are already myopic as well as those with normal vision or mild farsightedness. The study is conducted across multiple hospitals and aims to gather data over three years with follow-ups at six months, one year, and two years. The intervention involves the use of a headworn device that delivers 650nm low-intensity red light to the eyes. This device has been approved for safety and is used by children in everyday settings, not just within the study. The study observes children who are already receiving this red-light treatment, without providing additional interventions, and excludes participants using certain medications like atropine due to safety concerns. Participants will be monitored through regular assessments including measurements of eye axial length and spherical equivalent error at baseline and follow-up visits. Additional eye health measures such as choroid thickness, keratometry, lens thickness, anterior chamber depth, and corneal thickness will also be tracked. The study collects data on these outcomes to understand the red-light treatment's role in myopia control over the study period.

A Real-world Study of 650nm Low-intensity Single-wavelength Red Light for Children and Adolescents